# US 2012/0252816 A1 · Use of phosphodiesterase inhibitors for treating multidrug resistance

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252816 A1
- Document ID: US20120252816A1
- Status: Published application
- Kind: A1
- Application number: 13/432,315
- Filed: 2012-03-28
- Published: 2012-10-04
- Earliest claimed: 2011-03-28
- Assignees: St. John's University
- Inventors: Zhe-Sheng CHEN; Zhi SHI; Charles R. ASHBY, JR.
- Web page: https://patentgrep.com/patent/US20120252816A1

## CPC

- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods of treating multidrug resistance in cancerous cells with phosphodiesterase (PDE) inhibitors, e.g., PDE5 inhibitors. More specifically, the invention relates to methods of treating multidrug resistance that arises, e.g., during administration of chemotherapeutic/antineoplastic (anticancer) agents for treatment of cancer, with a PDE5 inhibitor (e.g., sildenafil, vardenafil, and tadalafil). The invention also relates to methods of treating cancer, e.g., multidrug resistant cancer, using a PDE5 inhibitor in combination with an antineoplastic therapeutic agent. Further, the invention relates to pharmaceutical compositions for treating multidrug resistant cancers comprising a PDE5 inhibitor, or a combination of a PDE5 inhibitor and an antineoplastic agent.

## Claims

### Claim 1

A method of treating multidrug resistance in a cancer cell in a subject in need thereof by inhibiting ABCB1 transporter activity, comprising administering to the subject a therapeutically effective amount of a phosphodiesterase 5 (PDE5) inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the PDE5 inhibitor is selected from the group consisting of sildenafil, vardenafil, tadalafil, lodenafil, udenafil, benzamidenafil, mirodenafil, avanafil, zaprinast, SLX-2101, UK-371,800, UK-122764, icariin, DA-8159, 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]-pyrazin-2(1H)-one, and their analogs.

### Claim 3 (depends on 2)

The method of claim 2, wherein the PDE5 inhibitor is sildenafil.

### Claim 4 (depends on 2)

The method of claim 2, wherein the PDE5 inhibitor is vardenafil.

### Claim 5 (depends on 2)

The method of claim 2, wherein the PDE5 inhibitor is tadalafil.

### Claim 6 (depends on 1)

The method of claim 1, wherein the PDE5 inhibitor is administered in combination with an antineoplastic agent.

### Claim 7 (depends on 6)

The method of claim 6, wherein the antineoplastic agent is selected from the group consisting of antineoplastic agents listed in Table 1.

### Claim 8 (depends on 7)

The method of claim 7, wherein the antineoplastic agent is selected from the group consisting of paclitaxel, vinblastine, and vincristine.

### Claim 9

A method of treating multidrug resistance in a cancer cell in a subject in need thereof by inhibiting ABCG2 transporter activity, comprising administering to the subject a therapeutically effective amount of a PDE5 inhibitor.

### Claim 10 (depends on 9)

The method of claim 9, wherein the PDE5 inhibitor is selected from the group consisting of sildenafil, lodenafil, udenafil, benzamidenafil, mirodenafil, avanafil, zaprinast, SLX-2101, UK-371,800, UK-122764, icariin, DA-8159, 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]-pyrazin-2(1H)-one, and their analogs.

### Claim 11 (depends on 10)

The method of claim 10, wherein the PDE5 inhibitor is sildenafil.

### Claim 12 (depends on 9)

The method of claim 9, wherein the PDE5 inhibitor is administered in combination with an antineoplastic agent.

### Claim 13 (depends on 12)

The method of claim 12, wherein the antineoplastic agent is selected from the group consisting of antineoplastic agent listed in Table 2.

### Claim 14 (depends on 13)

The method of claim 13, wherein the antineoplastic agent is selected from the group consisting of SN-38, flavopiridol, mitoxantrone, and methotrexate.

### Claim 15

A method of treating multidrug resistance in a cancer cell in a subject in need thereof by inhibiting ABCC10 transporter activity, comprising administering to the subject a therapeutically effective amount of a PDE5 inhibitor.

### Claim 16 (depends on 15)

The method of claim 15, wherein the PDE5 inhibitor is selected from the group consisting of sildenafil, vardenafil, tadalafil, lodenafil, udenafil, benzamidenafil, mirodenafil, avanafil, zaprinast, SLX-2101, UK-371,800, UK-122764, icariin, DA-8159, 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]-pyrazin-2(1H)-one, and their analogs.

### Claim 17 (depends on 16)

The method of claim 16, wherein the PDE5 inhibitor is sildenafil.

### Claim 18 (depends on 16)

The method of claim 16, wherein the PDE5 inhibitor is vardenafil.

### Claim 19 (depends on 15)

The method of claim 15, wherein the PDE5 inhibitor is administered in combination with an antineoplastic agent.

### Claim 20 (depends on 19)

The method of claim 19, wherein the antineoplastic agent is selected from the group consisting of antineoplastic agents listed in Table 3.

### Claim 21 (depends on 20)

The method of claim 20, wherein the antineoplastic agent is selected from the group consisting of paclitaxel, docetaxel, vinblastine, and vincristine.
